Adverse proinflammatory responses in the kidney after FGF23 administration in murine kidney disease models
FGF23 is a biomarker associated with morbidity and mortality, but controversies remain if a causative link exists between FGF23 excess and adverse renal consequences in chronic kidney disease (CKD).  Here, we investigated renal FGF23 signaling in kidney disease models in mice, with a focus on adverse pro-inflammatory effects assessed in bulk transcriptomes. Overall design: To investigate renal effects of FGF23 hormone in kidney disease, we assessed bulk transcriptomes in kidney of FGF23 or vehicle treated mice that were i) healthy males or males with anti-glomerular basement membrane disease receiving 6 days of treatments, ii) healthy females or females with adriamycin nephroathy receiving 24h of treatment, and iii) adenine nephropathy mouse kidney tissue receiving ex vivo treatment for 1h in precision-cut kidney slices (PCKS).